Diabetic cardiomyopathy is characterized by cardiac dysfunction. This study was designed to examine the effect of benfotiamine, a lipophilic derivative of thiamine, on streptozotocin (STZ)-induced cardiac contractile dysfunction in mouse cardiomyocytes. Adult male FVB mice were made diabetic with a single injection of STZ (200 mg/kg, i.p.). Fourteen days later, control and diabetic (fasting plasma glucose > 13.9 mM) mice were put on benfotiamine therapy (100 mg/kg/d, . Diabetes triggered oxidative stress, measured by GSH/GSSG ratio and formation of advanced glycation end-product (AGE) in the hearts. Benfotiamine treatment alleviated oxidative stress without affecting AGE or protein carbonyl formation. Collectively, our results indicated benfotiamine may rescue STZ-induced cardiomyocyte dysfunction but unlikely AGE formation in short-term diabetes.
JAP-00988-2005.R3

INTRODUCTION
Diabetes mellitus leads to high cardiovascular morbidity and mortality as a result of functional and morphological damage in diabetic hearts (20; 21) . A unique myopathic alteration, namely diabetic cardiomyopathy, has been established independent of macro-or micro-vascular diseases commonly seen in diabetes (20) . The most prominent defects of diabetic cardiomyopathy are prolonged duration of contraction and relaxation, as well as reduced cardiac compliance (19) (20) (21) . The etiology of diabetic cardiomyopathy is rather complex and involves metabolic derangements, depressed autonomic function and abnormalities in certain hormones or proteins which regulate intracellular ion homeostasis, particularly Ca 2+ (8; 16; 20) . The high mortality of diabetic heart complications warrants stringent and aggressive treatment against hyperglycemia, hyperinsulinemia, dyslipidemia and oxidant damage. Classical therapeutic agents against diabetic heart diseases include angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor antagonists, digoxin, diuretics, D-blockers, Ca 2+ antagonists and spironolactone. Both enzymatic and non-enzymatic antioxidants have been proven to be effective against diabetic heart complications (15; 24; 29). Insulin-sensitizing or lipid reducing agents such as thiazolidinediones and peroxisome proliferators-activated receptors (PPARs) agonists have also shown promises for various types of diabetic complications (18) . In addition to pharmacological interventions, lifestyle changes such as smoking cessation, weight control, exercise and dietary restriction have all been included in the primary care for diabetes mellitus (14) . Nevertheless, none of these therapeutic strategies may be considered the panacea for optimal and ultimate management of high morbidity and mortality of diabetic heart complications.
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4 (AGE) formation and other signaling or metabolic pathways (10) . AGE accumulation occurs under hyperglycemic and diabetic environments where elevated oxidative stress is usually present (10) . AGE binds to its cell-surface receptor, RAGE, resulting in the activation of postreceptor signaling, generation of intracellular reactive oxygen species and alteration of gene expression (13; 23) . The finding that thiamine interrupts AGE formation (10) may be related to a so-called "AGE-breaker" effect; that is, the ability to cleave dicarbonyl bonds formed during advanced glycation (26) . The clinical potential of thiamine in diabetic therapeutics is consistent with the notion that this vitamin may be depleted as a result of diabetes-induced oxidative stress or glucose autoxidation where thiamine is oxidized into the biologically nonfunctional products thiochrome and oxodihydrothiochrome (17) . Deficiencies in B series vitamins and folic acid are among the key causative factors leading to diabetic organ damage, consistent with the high incidence of idiopathic dilated cardiomyopathy in patients with vitamin-deficiency (25) . Group B vitamins, which may be acquired through dietary intake, are important water-soluble vitamins essential for DNA synthesis and repair. To further examine the impact of thiamine supplementation on cardiomyocyte function in diabetes, type 1 experimental diabetes was induced with a single injection of streptozotocin (STZ) in FVB albino mice. Both control and diabetic mice received 14-day oral treatment of benfotiamine, a lipophilic derivative of thiamine.
State-of-the-art cell physiological techniques were employed to examine the mechanical and intracellular Ca 
MATERIALS AND METHODS
Experimental Animals and Benfotiamine Therapy
The procedures described here were approved by the Institutional Animal Care and Use Committee of University of Wyoming (Laramie, WY) and were in accordance with NIH animal care standards. Eight week-old male FVB albino mice (16 -20 g ) were injected with a single dose of streptozotocin (STZ, 200 mg/kg., i.p. in 0.01 M citrate buffer with a pH of 4.3) (9). Nondiabetic control mice (weight-matched) received citrate buffer only. Fasting plasma glucose was examined after 3 and 14 days of STZ injection and diabetes was confirmed by fasting plasma glucose value of 13.9 mM or higher using ACCU-CHEK Advantage Glucometer (Boehringer Mannheim Diagnostics, Indianapolis, IN). On day 15 of STZ or citrate injection, both diabetic and nondiabetic control mice were randomly divided into two experimental groups with only one group being gavaged with benfotiamine (100 mg/kg/d) for two weeks. Selection of the benfotiamine dose (100 mg/kg/d) and duration of treatment were chosen based on previously published data for the thiamine derivative (2; 3; 10). Mice were maintained on a 12/12-light/dark cycle and were allowed access to food and water ad libitum. A cohort of confirmed diabetic mice (without benfotiamine treatment) was sacrificed on day 15 to evaluate cardiomyocyte function.
All other mice were sacrificed four weeks after STZ or citrate injection. Plasma glucose levels were measured again at the time of sacrifice and were included in table 1.
Ventricular Myocytes Isolation Procedures
Hearts were rapidly removed from anesthetized mice and immediately mounted on a temperature-controlled (37°C) Langendorff perfusion system. After perfusion with modified Tyrode 
Protein Carbonyl Assay
To assess cardiac oxidative protein damage, the carbonyl content of protein was extracted from mitochondria and was lysed to prevent proteolytic degradation. Nucleic acids were eliminated by treating the samples with 1% streptomycin sulfate for 15 min, followed by a 10 min centrifugation (11,000 x g). Protein was precipitated by adding an equal volume of 20% trichloroacetic acid (TCA) to protein (0.5 mg) and centrifuged for 1 min. The TCA solution was removed and the sample resuspended in 10 mM 2,4-dinitrophenylhydrazine (2,4-DNPH) solution. Samples were incubated at room temperature for 15-30 min. 500 Ql of 20% TCA was added and samples centrifuged for 3 min. The resultant supernatant was discarded, the pellet was washed in ethanol:ethyl acetate and allowed to incubate at room temperature for 10 min. The samples were centrifuged again for 3 min and the ethanol:ethyl acetate steps were repeated twice more. The precipitate was resuspended in 6 M guanidine solution, centrifuged for 3 min and insoluble debris was removed. The maximum absorbance (360-390 nm) was read against blank (2 M HCl) and the carbonyl content was calculated using the molar absorption coefficient of 22,000 M -1 cm -1 (11) .
Glutathione and glutathione disulfide (GSH/GSSG) assay
Glutathione levels were determined and the ratio of GSH/GSSG was used as an indicator for oxidative stress. In brief, samples were homogenized in 4 volumes (w/v) of 1% picric acid.
Acid homogenates were centrifuged at 16,000 x g (30 min) and supernatant fractions collected.
Supernatant fractions were assayed for total GSH and GSSG by the standard recycling method.
The procedure consisted of using one-half of each sample for GSSG determination and the other half for GSH. Samples for GSSG determination were incubated at room temperature with 2 µl of 4-vinyl pyridine (4-VP) per 100 µl sample for 1 hr after vigorous vortexing. Incubation with 4-VP conjugates any GSH present in the sample so that only GSSG is recycled to GSH without interference by GSH. The GSSG (as GSHx2) was then subtracted from the total GSH to determine actual GSH level and GSH/GSSG ratio (22) .
Western Blot Analysis of AGE and Phospholamban
Tissue samples from ventricles were removed and homogenized in a lysis buffer The membrane was then exposed to 2 ml of a mixture of luminol plus hydrogen peroxide under alkaline conditions (SuperSignal® West Dura Extended Duration Substrate, Pierce, Rockford, IL) for 1 min, and the resulting chemiluminescent reaction was detected by Kodak X-OMAT AR Film (Eastman Kodak, Rochester, NY) (8).
Statistical Analyses
An average of 5-7 mice was used per group (control and diabetic with or without benfotiamine) for mechanical and intracellular Ca 
RESULTS
General Features of Experimental Animals
Four weeks of STZ treatment significantly increased fasting plasma glucose levels and reduced body weight gain. The absolute organ (heart, liver and kidney) weight or organ-to-body weight ratio was comparable between control and STZ-induced diabetic groups. Two weeks of benfotiamine treatment (100 mg/kg/d) did not elicit any significant effect on fasting plasma glucose levels, body, organ weight or organ-to-body weight ratio in either control or STZ diabetic mouse group (Table 1) . Two weeks of STZ treatment produced biometric change similar to those found in 4 weeks STZ mice when compared with their age-matched non-diabetic controls (data not shown).
Cell Shortening and Relengthening Properties of Myocytes
There was no significant difference in resting cell length of ventricular myocytes from (Fig. 2) .
Effect of Benfotiamine on Oxidative Stress, Protein Carbonyl Formation and AGE
Accumulation in Control and Diabetic Mouse Hearts
Diabetes is often associated with enhanced oxidative stress leading to irreversible damage of membrane proteins or lipids (27) . The glutathione (GSH) and glutathione disulfide (GSSG) levels are commonly used markers for oxidative stress. A low GSH/GSSG ratio suggests increased oxidative stress. Result in Fig. 3 indicates that 4 weeks STZ treatment-induced diabetes displayed significantly lowered GSH/GSSG ratio, suggesting enhanced cardiac oxidative stress.
Protein carbonyl formation, an indicative of protein damage, was not altered by 4 weeks STZinduced diabetes or benfotiamine. Two weeks STZ treatment also lowered GSH/GSSG ratio without affecting protein carbonyl formation, similar to those elicited by 4 weeks STZ treatment (data not shown). Since AGE accumulation may serve as a main source for oxidative stress (13; (Fig. 4) .
We also evaluated the effect of benfotiamine on expression of phospholamban, a key intracellular Ca 
DISCUSSION
Our study reported for the first time beneficial effects of the lipophilic derivative of thiamine -benfotiamine on diabetic cardiac dysfunction. In addition, we found that benfotiamineelicited beneficial effects for diabetic heart dysfunction may be related to, at least in part, reduced oxidative stress but less likely AGE accumulation in diabetic hearts. Our results did not favor any major role of cardiac protein damage or Ca 2+ regulatory protein phospholamban in benfotiamineexerted beneficial effects in diabetes-associated cardiac dysfunction.
Prolonged duration of both contraction and relaxation duration is considered a hallmark of diabetic cardiomyopathy (12; 20; 27) . Somewhat similar to our earlier observations using chemically-induced or genetic models of diabetes (8; 19; 21) , our present study demonstrated in response to electrical stimuli in control mouse group (Fig. 2B) is unknown, it may be speculated that benfotiamine is capable of promoting myofilament Ca Our present study revealed that benfotiamine treatment counters diabetes-induced cardiac mechanical dysfunction at cellular level associated with reduction in oxidative stress but unlikely AGE formation or cardiac protein carbonyl formation. This apparent discrepancy in benfotiamine-elicited action on AGE formation and oxidative stress (GSH/GSSG ratio), seems to indicate that other mechanism(s) may predominantly contribute to diabetes-induced oxidative stress and cardiac contractile dysfunction in current experimental setting. Possible candidates may include alteration in glucose metabolism and protein kinase C activation (5; 20) although further study is warranted to verify involvement of these signaling pathways and beneficial effects of benfotiamine against diabetic cardiomyopathy. In addition, benfotiamine may directly participate in glucose metabolic regulation. Thiamine and benfotiamine were demonstrated to activate the pentose phosphate pathway enzyme transketolase, facilitating conversion of glyceraldehyde-3-phosphate and fructose-6-phosphate into pentose-5-phosphates (10; 17).
Finally, the observation that benfotiamine treatment failed to produce any overt cardiac hypertrophic response should indicate that ventricular remodeling is unlikely a concern for the clinical application of benfotiamine. It is noteworthy that we failed to observe cardiac hypertrophy following STZ treatment in our current study. Although STZ has been reported to induce cardiac hypertrophy and does so largely through genomic adaptive or maladaptive process (7), the period of diabetes employed in our present study (4 weeks) may not be long enough to induce such cardiac remodeling process.
Experimental limitations: Our study employed a short-term (2 to 4 weeks) STZ-induced type 1 diabetic model, this diabetic model may not represent the most prevalent chronic type 2 diabetes. Further work using ob/ob and db/db type 2 diabetic models is warranted to provide convincing evidence regarding the therapeutic effectiveness of benfotiamine against diabetic cardiomyopathy. In addition, the potential direct cardiac toxicity of STZ (28) 
